Mar­ket­ingRx roundup: Pfiz­er de­buts Pre­vnar 20 TV ads; Lil­ly gets first FDA 2022 pro­mo slap down let­ter

Pfiz­er de­buted its first TV ad for its Pre­vnar 20 next-gen­er­a­tion pneu­mo­coc­cal pneu­mo­nia vac­cine. In the 60-sec­ond spot, sev­er­al peo­ple (ac­tor por­tray­als) with their ages list­ed as 65 or old­er are shown walk­ing in­to a clin­ic as they turn to say they’re get­ting vac­ci­nat­ed with Pre­vnar 20 be­cause they’re at risk.

The up­date to Pfiz­er’s block­buster Pre­vnar 13 vac­cine was ap­proved in June, and as its name sug­gests is a vac­cine for 20 serotypes — the orig­i­nal 13 plus sev­en more that cause pneu­mo­coc­cal dis­ease. Pfiz­er used to spend heav­i­ly on TV ads to pro­mote Pre­vnar 13 in 2018 and 2019 but cut back its TV bud­gets in the past two fall and win­ter sea­son­al spend­ing cy­cles. Pre­vnar had been Pfiz­er’s top-sell­ing drug, notch­ing sales of just un­der $6 bil­lion in 2020, and was the world’s top-sell­ing vac­cine be­fore the Covid-19 vac­cines came to mar­ket last year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.